Appendix A
Agenda

8:00–8:10

Objectives of the Workshop

 

Gail Cassell, Eli Lilly and Company

 

Workshop Chair

8:10–9:40

Panel I: SETTING THE STAGE

10-minute presentations followed by a 30-minute panel discussion

 

Moderator: Kenneth Castro, Centers for Disease Control and Prevention

 

Paul Nunn, World Health Organization

Global Incidence of MDR TB

 

Yanis Ben Amor, Earth Institute

Underreported Threat of MDR TB in Africa

 

Gerald Friedland, Tugela Ferry Care and Research Collaboration

HIV/MDR-XDR TB: Implications

Megan Murray, Brigham and Women’s Hospital

Number of MDR TB and XDR TB Patients Receiving Treatment Today: Successes/Failures/Consequences

 

Qian Gao, Shanghai Medical College

Transmission of MDR TB



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement



Below are the first 10 and last 10 pages of uncorrected machine-read text (when available) of this chapter, followed by the top 30 algorithmically extracted key phrases from the chapter as a whole.
Intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text on the opening pages of each chapter. Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.

Do not use for reproduction, copying, pasting, or reading; exclusively for search engines.

OCR for page 113
Appendix A Agenda 8:00–8:10 Objectives of the Workshop Gail Cassell, Eli lilly and Company Workshop Chair 8:10–9:40 Panel I: SETTING THE STAGE 10-minute presentations followed by a 30-minute panel discussion Moderator: kenneth Castro, Centers for Disease Control and Preention Paul Nunn, World Health Organization Global Incidence of MDR TB yanis ben Amor, Earth Institute Underreported Threat of MDR TB in Africa Gerald Friedland, Tugela Ferry Care and Research Collaboration HIV/MDR-XDR TB: Implications Megan Murray, brigham and Women’s Hospital Number of MDR TB and XDR TB Patients Receiving Treatment Today: Successes/Failures/Consequences Qian Gao, Shanghai Medical College Transmission of MDR TB 

OCR for page 113
 THREAT OF DRug-RESISTANT TubERCulOSIS Neel Gandhi, Tugela Ferry Care and Research Collaboration Transmission of XDR TB 9:40–9:50 break 9:50–11:30 Panel II: HOW DID WE GET TO WHERE WE ARE TODAy: DIFFERENT PERSPECTIvES 10-minute presentations followed by a 40-minute panel discussion Moderator: Richard Chaisson, Johns Hopkins uniersity Edward Nardell, brigham and Women’s Hospital Lack of Infection Control John Ridderhof, Centers for Disease Control and Preention Laboratory Capacity: A Global Analysis Anne Goldfeld, Harard School of Public Health Drug and Health Care Delivery: Cambodian and Ethiopian Perspectives Wieslaw Jakubowiak, WHO Country Office Russian Federation Fighting Drug Resistance in Russia: Challenges and Achievements Paul Zintl, Partners In Health Drug Supply: The Stop TB Partnership Perspective Ruth Levine, Center for global Deelopment Critical Role of Accurate Demand Forecasting: Lessons Learned from Malaria 11:30–12:30 Lunch 12:30–1:20 keynote Address: The Research Path to Tuberculosis Control: An NIH Perspective Anthony Fauci, National Institute of Allergy and Infectious Diseases 1:20–3:00 Panel III: ESSENTIAL buILDING bLOCkS 10-minute presentations followed by a 20-minute panel discussion Moderator: Leonard Sacks, Food and Drug Administration

OCR for page 113
 APPENDIx A Dale Nordenberg and Hamish Fraser, brigham and Women’s Hospital Knowledge Management (IT): What Do We Need and What Do We Have? David Persing, Cepheid, and Charles Daitch, Akonni biosystems Point-of-Care Diagnostics: How Close Are We? Ann Ginsberg, Tb Alliance TB Drug Development: Realities of the Pipeline Raymond Woosley, The Critical Path Institute Critical Path for Parallel Development of TB Point-of- Care Diagnostic and Drug Development Jeff Moe, Duke uniersity What Are the Odds? Who Will Pay? What Are the Incentives? 3:00–3:15 break 3:15–4:15 Panel III: A bLuEPRINT FOR ACTION Moderator: Peter Cegielski, Centers for Disease Control and Preention Salmaan keshavjee, Partners In Health The Plan: From Powder to Patient Discussants: Michael kimerling, bill and Melinda gates Foundation Carol Nacy, Sequella, Inc. Iain Richardson, Eli lilly and Company Caroline Ryan, u.S. Department of State Sarita Shah, Tugela Ferry Care and Research Collaboration Alexander Sloutsky, uniersity of Massachusetts Martie van der Walt, Medical Research Council South Africa Charles Wells, Otsuka 4:15–5:30 Panel v: THE NEED FOR uRGENCy 15-minute presentations followed by 45-minutes of discussion Moderator: Jim yong kim, Partners In Health

OCR for page 113
 THREAT OF DRug-RESISTANT TubERCulOSIS Mark Harrington, Treatment Action group Lessons from HIV Paul Farmer, Partners In Health Lessons from MDR TB 5:30 SyNTHESIS AND NEXT STEPS Gail Cassell, Eli lilly and Company Workshop Chair